Last reviewed · How we verify
Dexlansoprazole Delayed Release Capsules — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Dexlansoprazole Delayed Release Capsules (Dexlansoprazole Delayed Release Capsules) — Takeda. Blocks the H+/K+ ATPase enzyme system (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dexlansoprazole Delayed Release Capsules TARGET | Dexlansoprazole Delayed Release Capsules | Takeda | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dexlansoprazole Delayed Release Capsules CI watch — RSS
- Dexlansoprazole Delayed Release Capsules CI watch — Atom
- Dexlansoprazole Delayed Release Capsules CI watch — JSON
- Dexlansoprazole Delayed Release Capsules alone — RSS
Cite this brief
Drug Landscape (2026). Dexlansoprazole Delayed Release Capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/dexlansoprazole-delayed-release-capsules. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing